What are the pharmacological effects and clinical applications of ensidipine?

Enasidenib is a targeted drug for specific types of leukemia. It is mainly used to treat relapsed or refractory acute myeloid leukemia (AML) in adults carrying isocitrate dehydrogenase 2 (IDH2) gene mutations. Its pharmacological effect is to inhibit the proliferation and survival of leukemia cells by inhibiting the activity of mutant IDH2 enzyme and blocking abnormal metabolic pathways. In clinical applications, ensidipine is usually used as a monotherapy or in combination with other chemotherapy drugs to improve survival and symptom relief in AML patients. Clinical trials have shown that ensidipine has good efficacy in some AML patients, can significantly extend progression-free survival, and achieve complete remission in some cases.